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Abstract
Multi-omics data, that is, datasets containing different types of high-dimensional molecular
variables (often in addition to classical clinical variables), are increasingly generated for the inves-
tigation of various diseases. Nevertheless, questions remain regarding the usefulness of multi-omics
data for the prediction of disease outcomes such as survival time. It is also unclear which methods
are most appropriate to derive such prediction models. We aim to give some answers to these
questions by means of a large-scale benchmark study using real data. Different prediction meth-
ods from machine learning and statistics were applied on 18 multi-omics cancer datasets from the
database "The Cancer Genome Atlas", containing from 35 to 1,000 observations and from 60,000
to 100,000 variables. The considered outcome was the (censored) survival time. Twelve meth-
ods based on boosting, penalized regression and random forest were compared, comprising both
methods that do and that do not take the group structure of the omics variables into account.
The Kaplan-Meier estimate and a Cox model using only clinical variables were used as reference
methods. The methods were compared using several repetitions of 5-fold cross-validation. Uno’s
C-index and the integrated Brier-score served as performance metrics. The results show that, al-
though multi-omics data can improve the prediction performance, this is not generally the case.
Only the method block forest slightly outperformed the Cox model on average over all datasets.
Taking into account the multi-omics structure improves the predictive performance and protects
variables in low-dimensional groups—especially clinical variables—from not being included in the
model. All analyses are reproducible using freely available R code.
Keywords: multi-omics data, prediction models, benchmark, survival analysis, machine learning,
statistics
1 Introduction
In the last two decades, high-throughput technologies have made data stemming from molecular
processes available on a large scale (“omics data”) and for many patients. Starting from the anal-
ysis of whole genomes, other molecular entities such as mRNA or peptides have also come into
focus with the advancing technologies. Thus, various types of omics variables are currently under
investigation across several disciplines such as genomics, epigenomics, transcriptomics, proteomics,
metabolomics, and microbiomics (Hasin et al., 2017).
It may be beneficial to include these different data types in models predicting outcomes, such
as the survival time of patients. Until recently, only data from a single omics type was used to build
such prediction models, with or without inclusion of standard clinical data (Boulesteix and Sauerbrei,
2011). In recent years, however, the increasing availability of different types of omics data mea-
sured for the same patients (called “multi-omics data” from now on) has led to their combined
use for building outcome prediction models. An important characteristic of multi-omics data is
the high-dimensionality of the datasets, which frequently have more than 10,000 or even 100,000
variables. This places particular demands on the methods used to build prediction models: they
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must be able to handle data where the number of variables by far exceeds the number of observa-
tions. Moreover, practitioners often prefer sparse and interpretable models containing only a few
variables (Klau et al., 2018). Last but not least, multi-omics data are structured: the variables are
partitioned into (non-overlapping) groups. This structure may be taken into account when building
prediction models.
Several methods have been specifically proposed to handle multi-omics data, while established
methods for high-dimensional data from the fields of statistics and machine learning also seem
reasonable for use in this context. Although there are studies with a limited scope comparing some
of these methods, there has not yet been a large-scale systematic comparison of their pros and cons
in the context of multi-omics using a sufficiently large amount of real data.
The pioneering study by Bøvelstad et al. (2009) investigates the combined use of clinical and one
type of molecular data, using only four datasets. In one of the first studies devoted to methodological
aspects of multi-omics-based prediction models, Zhao et al. (2014) compare a limited number of
methods for multi-omics data based on a limited number of datasets. Lang et al. (2015) investigate
automatic model selection in high-dimensional survival settings, using similar but fewer prediction
methods than our study. Moreover, again only four datasets are used. A study by De Bin et al.
(2019) investigates the combination of clinical and molecular data, with a focus on the influence of
correlation structures of the feature groups, but it is based on simulated data.
Our study aims to fill this gap by providing a large-scale benchmark experiment for prediction
methods using multi-omics data. It is based on 18 cancer datasets from the Cancer Genome
Atlas (TCGA) and focuses on survival time prediction. We use several variants of three widely
used modeling approaches from the fields of statistics and machine learning: penalized regression,
statistical boosting, and random forest. The aim is to assess the performances of the methods, the
different ways to take the multi-omics structure into account, and the added predictive value of
multi-omics data over models using only clinical variables.
The remainder of the paper is structured as follows. The Methods section briefly outlines the
methods under investigation. In the subsequent Benchmark experiment section we describe the
conducted experiment. The findings are presented in the Results section, which is followed by a
discussion.
2 Methods
2.1 Preliminary remarks
There are essentially two ways to include multi-omics data in a prediction model. The first approach,
which we term as “naive”, does not distinguish the different data types, i.e. does not take the
group structure into account. In the second approach, the group structure is taken into account.
The advantage of the naive approach, its simplicity, comes at a price. First of all, physicians
and researchers often have some kind of prior knowledge of which data type might be especially
useful in the given context (Klau et al., 2018). If so, it is desirable to include such information by
incorporating the group structure. Well-established prognostic clinical variables which are known
to be beneficial for building prediction models for a specific disease are an important special case.
In this situation, it may be useful to take the group structure into account during model building
or even to treat clinical variables with priority. Otherwise these clinical variables might get lost
within the huge amount of omics data (Boulesteix and Sauerbrei, 2011). To some extent, the same
might be true for different kinds of omics data. If, for example, gene expression is expected to be
more important than copy number variation data for the purpose of prediction, it might be useful
to incorporate the distinction between these two data types into the prediction model or even to
prioritize gene expression in some sense.
Other important aspects of prediction models from the perspective of clinicians are sparsity,
interpretability and transportability (Klau et al., 2018). Methods yielding models which are sparse
with regard to the number of variables and number of omics types are often considered preferable
from a practical perspective. Interpretation and practical application of the model to the prediction
of independent data are easier with regression-based methods yielding coefficients that reflect the
effects of variables on the outcome, than with machine learning algorithms (Boulesteix et al., 2019).
Finally, in addition to the prediction performances of the different methods, the question
of the additional predictive value of omics data compared to clinical data is also interesting
from a clinical perspective (Boulesteix and Sauerbrei, 2011). Many of the omics-based predic-
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tion models which were claimed to be of value for predicting disease outcomes could eventually not
be shown to outperform clinical models in independent studies (Boulesteix and Sauerbrei, 2011;
Bøvelstad et al., 2009; De Bin et al., 2014). However, some findings suggest that using both clini-
cal and omics variables jointlymay outperform clinical models (Bøvelstad et al., 2009; De Bin et al.,
2014; Binder and Schumacher, 2008). In our benchmark study, we can address this issue by sys-
tematically comparing the performance of clinical models and combined models for a large number
of datasets.
The methods included in our study can be subsumed in three general approaches, which are
briefly described in the following subsections: penalized-regression-based methods, boosting-based
methods and random-forest-based methods. A more technical description of the methods can be
found in the supplementary material. Additionally, two reference methods are considered: simple
Cox regression, which only uses the clinical variables, and the Kaplan-Meier estimate, which does
not use any information from the predictor variables.
2.2 Penalized-regression-based methods
The penalized regression methods briefly reviewed in this section have in common that they modify
maximum partial likelihood estimation by applying a regularization, most importantly to account
for the n << p problem.
Standard Lasso, introduced more than two decades ago (Tibshirani, 1996) and subsequently
extended to survival time data (Tibshirani, 1997), applies L1-regularization to penalize large (ab-
solute) coefficient values. The result is a sparse final model: a number of coefficients are set to zero.
The number of non-zero coefficients decreases with increasing penalty parameter λ and cannot ex-
ceed the sample size. The method does not take the group structure into account. The parameter
λ is a hyper-parameter to be tuned.
Two-step (TS) IPF-Lasso (Schulze, 2017) is an extension of the standard Lasso specifically
designed to take a multi-omics group structure into account. This method is an adaptation of the
integrative Lasso with penalty factors (IPF) (Boulesteix et al., 2017), which consists in allowing
different penalty values for each data type. In TS-IPF-Lasso, the ratios between these penalty
values are determined in a first step (roughly speaking, by applying standard Lasso and averaging
the resulting coefficients).
Priority-Lasso (Klau et al., 2018) is another Lasso-based method designed for the incorporation
of different groups of variables. Often clinical researchers prioritize variables that are easier, cheaper
to measure or known to be good predictors of the outcome. The principle of priority-Lasso is to
define a priority order for the groups of variables. Priority-Lasso then successively fits Lasso-
regression models to these groups, whereby at each step the resulting linear predictor is used as an
offset for the Lasso model fit to the next group. For the study at hand, however, we do not have
any substantial domain knowledge, so we cannot specify a meaningful priority order. We therefore
alter the method into a two-step procedure similar to the TS IPF-Lasso. More precisely, we order
the groups of variables according to the mean values of their coefficients fitted in the first step by
separately modeling each group. This ordering is used as a surrogate for a knowledge based priority
order.
Sparse Group Lasso (SGL) (Simon et al., 2013) is another extension of the Lasso, capable of
including group information. The method incorporates a convex combination of the standard Lasso
penalty and the group-Lasso penalty (Yuan and Lin, 2006). This simultaneously leads to sparsity
on feature as well as on group level.
Adaptive group-regularized ridge regression (GRridge) (Wiel et al., 2015) is designed to use
group specific co-data, e.g., p-values known from previous studies. Multi-omics group structure
may also be regarded as co-data, although the method was originally not intended for this purpose.
It is based on ridge regression, which uses a L2-based penalty term. Feature selection is achieved
post-hoc by exploiting the heavy-tailed distribution of the estimated coefficients, which clearly
separates coefficients close to zero from those which are further away (Wiel et al., 2015).
2.3 Boosting-based methods
Boosting is a general technique introduced in the context of classification in the machine learning
community, which has then been revisited in a statistical context (Friedman, 2001). Statistical
boosting can be seen as a form of iterative function estimation by fitting a series of weak models,
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so called base learners. In general, one is interested in a function that minimizes the expected
loss when used to model the data. This target function is updated iteratively, with the number
of boosting steps mstop, i.e. the number of iterations, being the main tuning parameter. This
parameter, together with the so-called learning rate, which steers the contribution of each update,
also leads to a feature selection property. In this study we use two different boosting approaches.
Model-based boosting (Hothorn and Bühlmann, 2006), the first variant, uses simple linear models
as base learners and updates only the loss minimizing base learner per iteration. The learning rate
is usually fixed to a small value such as 0.1 (Bühlmann and Hothorn, 2007).
Likelihood-based boosting (Tutz and Binder, 2006), in contrast, uses a penalized version of the
likelihood as loss and the shrinkage is directly applied in the coefficient estimation step via a penalty
parameter. It is also an iterative procedure: the updates of previous iterations are included as an
offset to make use of the information gained.
2.4 Random-forest-based methods
Random forest is a tree-based ensemble method introduced by Breiman (2001). Instead of growing
a single classification or regression tree, it uses bootstrap aggregation to grow several trees and
averages the results. Random forest was later expanded to survival time data (Ishwaran et al.,
2008). For each split in each tree, the variable maximizing the difference in survival is chosen
as best feature. Eventually, the cumulative hazard function is computed via the Nelson-Aalen
estimator in each final node in each tree. For prediction, these estimates are averaged across the
trees to obtain the ensemble cumulative hazard function.
Block forest (Hornung and Wright, 2019) is a variant modifying the split point selection of
random forest to incorporate the group structure (or “block” structure, hence the name of the
method) of multi-omics data. It can be applied to any outcome type for which a random forest
variant exists.
3 Benchmark experiment
3.1 Study design
Our study is intended as a neutral comparison study; see Boulesteix et al. (2013, 2017) for an exact
definition and discussions of this concept. Firstly, we compare methods that have been described
elsewhere and do not aim at emphasizing a particular method. Secondly, we tried to achieve
a reasonable level of neutrality, which we disclose here following the example of Couronné et al.
(2018). As a team we are approximately equally familiar with all classes of methods. Some of us
have been involved in the development of priority-Lasso, IPF-Lasso and block forest. As far as the
other methods are concerned, we contacted the person listed in CRAN as package maintainer via
email and asked for an evaluation of our implementation including the choice of parameters.
A further important aspect of the study design is the choice and number of datasets used for the
comparison, since the performance of prediction methods usually strongly varies across datasets.
Boulesteix et al. (2017) compare benchmark experiments to clinical trials, where methods play the
role of treatments and datasets play the role of patients. In analogy to clinical trials, the number of
considered datasets should be chosen large enough to draw reliable conclusions, and the selection of
datasets should follow strict inclusion criteria and not be modified after seeing the results; see the
Datasets section for more details on this process. Finally, a benchmark experiment should be easily
extendable (and, of course, reproducible). It is almost impossible to include every available method
in a single benchmark experiment, and it should also be easy to compare methods proposed later
without re-running the full experiment and without too much programming effort. For this reason
we use the R package mlr (Bischl et al., 2016), which offers a unified framework for benchmark
experiments and makes them easily extendable and reproducible.
3.2 Technicalities and implementation
The benchmark experiment is conducted using R 3.5.1 (R Core Team, 2014). We compare the 14
learners described in the Method configurations section on 18 datasets (see the Datasets section).
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The code to reproduce the results is available on GitHub1, the data can be obtained from OpenML2
(Vanschoren et al., 2013; Casalicchio et al., 2017). To further improve reproducibility, the package
checkpoint (Microsoft Corporation, 2018) is used. Because the computations are time demanding
but parallelisable, the package batchtools (Lang et al., 2017) is used for parallelisation. The package
mlr (Bischl et al., 2016), used for this benchmark experiment, offers a simple framework to conduct
all necessary steps in a unified way.
We use 10 x 5-fold CV for datasets with a size less than 92 MB (11 datasets) and 5 x 5-fold
CV for datasets with a size larger than 112 MB (7 datasets) to keep computation times feasible.
Furthermore, we stratify the subsets, since the ratio of events and censorings is unbalanced for
some datasets. Moreover, hyperparameter tuning is performed. This could in principle also be
implemented via mlr, but in this study the tuning procedures provided by the specific packages are
used. We denote the resampling strategy used for hyper-parameter tuning inner-resampling and
the repeated CV used for performance assessment outer-resampling. For inner-resampling we use
out-of-bag-samples (OOB) for random forest learners and 10-fold CV for the other learners.
3.3 Performance evaluation
The performance is evaluated in three dimensions. First of all, the prediction performance is
assessed via the integrated Brier score and the C-index suggested by Uno et al. (2011) (hereinafter
simply denoted as ibrier and cindex).
The second dimension is the sparsity of the resulting models, which has two aspects: sparsity on
the level of variables and sparsity on group level. The latter refers to whether variables of only
some groups are selected. Sparsity on feature level, in contrast, refers to the overall sparsity, i.e.
the total number of selected features. As random forest does not perform variable selection, it is
not assessed in this dimension. Computation times are considered as a third dimension.
Another important aspect is the different use of group structure information. Some of the
methods do not use any such information, some favor clinical data over molecular data, and some
differentiate between all groups of variables (i.e., also between omics groups). Thus, the differences
in performance might not only result from using different prediction methods. They may also arise
from the way in which the group structure information is included. Therefore, comparability in
terms of predictive performance is only given for methods that use the same strategy to include
group information: (1) naive methods not using the group structure, (2) methods using the group
structure and not favoring clinical features, (3) methods using the group structure by favoring
clinical features, where we subsume methods favoring clinical and not distinguishing molecular
covariates, and methods favoring clinical and additionally also distinguishing molecular covariates.
3.4 Method configurations
Following the terminology of the package mlr (Bischl et al., 2016), we denote a method configu-
ration as a “learner”. There may be several learners based on the same method. An overview of
learners considered in our benchmark study is displayed in Table 1, while the full specification is
given in the paragraph devoted to the corresponding method. In the following, the R packages used
to implement the learners can be found in parentheses after the paragraph heading.
Penalized-regression-based learners
Lasso (glmnet Friedman et al. (2010); Simon et al. (2011))
The penalty parameter λ is chosen via internal 10-fold CV. No group structure information is used.
SGL (SGL Simon et al. (2018))
The model is fit via the cvSGL function. Tuning of the penalty parameter λ is conducted via in-
ternal 10-fold CV. The parameter α steering the contribution of the group-Lasso and the standard
Lasso is not tuned and set to the default value 0.95, as recommended by the authors (Simon et al.,
2013). All other parameters are set to default as well.
1https://github.com/HerrMo/multi-omics_benchmark_study
2https://www.openml.org/
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TS IPF-Lasso (ipflasso Boulesteix and Fuchs (2015))
The penalty factors are selected in the first step by computing separate ridge regression models for
every feature group and averaging the coefficients within the groups by the arithmetic mean. These
settings have shown reasonable results (Schulze, 2017). The choice of the penalty parameters λm
is conducted using 5-fold-CV in the first step and 10-fold CV in the second.
priority-Lasso (prioritylasso Klau and Hornung (2017))
The priority order is determined through a preliminary step realized in the same way as in the first
step of TS IPF-Lasso. The priority-Lasso method takes into account the group structure. Even
though the version with cross-validated offsets delivers slightly better prediction results (Klau et al.,
2018), the offsets are not estimated via CV in order to not increase the computation times further.
To select the parameter λ in each step of priority-Lasso, 10-fold CV is used.
priority-Lasso favoring clinical features (prioritylasso Klau and Hornung (2017))
The settings are the same as before, except that the group of clinical variables is always assigned the
highest priority. The preliminary step only determines the priority order for the molecular groups.
The clinical variables are used as an offset when fitting the model of the second group. Furthermore,
the clinical variables are not penalized (setting parameter block1.penalization = FALSE).
GRridge (GRridge Wiel and Novianti (2018))
This method was not originally intended for the purpose of including multi-omics group structure,
but is capable of doing so. To better fit the task at hand, a special routine was provided by the
package author in personal communication. In addition, the argument selectionEN is set to TRUE
so post-hoc variable selection is conducted, and maxsel, the maximum number of variables to be
selected, is set to 1000.
Boosting-based learners
Model-based boosting (mboost Hothorn et al. (2018))
Internally, mlr uses the function glmboost from the package mboost and sets the family argument
to CoxPH(). Furthermore the number of boosting steps (mstop) is chosen by a 10-fold CV on a grid
from 1 to 1000 via cvrisk. For the learning rate ν the default value of 0.1 is used. Group structure
information is not taken into account.
Likelihood-based boosting (CoxBoost Binder (2013))
The maximum number of boosting steps maxstepno is set to default, i.e. 100. Again, mstop is
determined by 10-fold CV. The penalty λ is set to default and thus computed according to the
number of events. No group structure information is used.
Likelihood-based boosting favoring clinical features (CoxBoost Binder (2013))
The settings are the same as before. Additionally, group structure information is used by specifying
the clinical features as mandatory. These features are favored as in the case of priority-Lasso by
setting them as an offset and not penalising them. Further group information is not used, so the
molecular data are not distinguished.
Random-forest-based learners
Random forest (randomForestSRC Ishwaran and Kogalur (2018); rangerWright and Ziegler (2017))
Two versions of standard random forest are examined: randomForestSRC (rfsrc) and ranger. They
share the same theoretical background, but differ in their implementation. Thus, two different
implementations are compared. Tuning of mtry is conducted via the tune function for rfsrc and
via the tuneMtryfast function of package tuneRanger for ranger. For tune the default settings
have been altered, firstly to match tuneMtryfast and secondly because they lead to infeasible com-
putation times. The minimal node size is 3 for both (the ranger default settings). The other
hyper-parameters are set to defaults.
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Block forest (blockForest Hornung and Wright (2019))
Block forest is a random forest variant able to include group structure information. The implemen-
tation is based on ranger. With function blockfor the models are fit via the default settings.
Reference methods
The clinical reference model is a Cox proportional hazard model, computed via the coxph func-
tion of the survival package (Therneau, 2015) and only uses clinical features. The Kaplan-Meier
estimate is computed via survfit from the same package.
3.5 Datasets
From the cancer datasets that have been gathered by the TCGA research network3, we selected
those with more than 100 samples and five different multi-omics groups, which resulted in a col-
lection of datasets for 26 cancer types. As described below, further preprocessing eventually lead
to 18 usable datasets. Table 2 lists all cancer types and the abbreviations used to reference them
within the study.
For each cancer type there are four molecular data types and the clinical data type, i.e. five
groups of variables. The molecular data types comprise copy number variation (cnv), gene expres-
sion (rna), miRNA expression (mirna), and mutation. The number of variables differs strongly
between groups but is similar across datasets. Most molecular features (about 60,000) belong to
the cnv group but only a few hundred features to mirna, the smallest group. There is a total of
about 80,000 to 103,000 molecular features for each cancer type.
Of the 26 available datasets, three were excluded because they did not have observations for
every data type. Furthermore, since the outcome of interest is survival time, not only the number
of observations is crucial but, most importantly, the number of events (deaths), which we call the
number of effective cases. A ratio of 0.2 of effective cases is common (De Bin et al., 2014). The
five datasets that had less than 5 % effective cases were excluded.
Since the majority of the clinical variables had missing values, the question arose of which
to include for a specific dataset while saving as many observations as possible. As we did not
have any domain knowledge, we adopted a two-step strategy. Firstly, an informal literature search
was conducted to find studies where the specific cancer type was under investigation. Variables
mentioned to be useful in these studies were included, if available. Secondly, we additionally used
variables that were available for most of the cancer types. These comprised sex, age, histological
type and tumor stage. These were included as standard, if available. Of course, sex was not
included for the sex-specific cancer types.
Table 1: Summary of learners used for the benchmark experiment. Use of group structure information is indicated by *.
learner method package::function tuning
Lasso Standard Lasso glmnet::cv.glmnet 10-f-CV
ipflasso* TS IPF-Lasso ipflasso::cvr.ipflasso 10-f-CV
prioritylasso* priority-Lasso priortiylasso::prioritylasso 10-f-CV
prioritylasso favoring* priority-Lasso priortiylasso::prioritylasso 10-f-CV
grridge* GRridge GRridge::grridge 10-f-CV
SGL* SGL SGL::cvSGL 10-f-CV
glmboost Model-based boosting mboost::glmboost 10-f-CV
CoxBoost Likelihood-based boosting CoxBoost::cv.CoxBoost 10-f-CV
CoxBoost favoring* Likelihood-based boosting CoxBoost::cv.CoxBoost 10-f-CV
rfsrc Random forest randomForestSRC::tune OOB
ranger Random forest tuneRanger::tuneMtryfast OOB
blockForest* Block forest blockForest::blockfor OOB
Clinical only Cox model survival::coxph no
Kaplan-Meier Kaplan-Meier estimate survival::survival no
3https://cancergenome.nih.gov
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Table 2: Summary of the datasets used for the benchmark experiment. The third to the seventh column show the number
of features in the feature group, the eighth column the total amount of features (p). The last three columns show, in
this order, the number of observations (n), the number of effective cases (n_e) and the ratio of the number of events and
the number of observations (r_e). Abbreviations: C. = Carcinoma, CC. = Cell Carcinoma, PP = Renal Papilla, AC. =
Adenocarcinoma, M. = Melanoma, EC. = Endometrial Carcinoma.
dataset cancer clin. cnv mirna mutation rna p n n_e r_e
BLCA Bladder Urothelial 5 57964 825 18577 23081 100455 382 103 0.27
BRCA Breast Invasive C. 8 57964 835 17975 22694 99479 735 72 0.10
COAD Colon Adenocarcinoma 7 57964 802 18538 22210 99524 191 17 0.09
ESCA Esophageal C. 6 57964 763 12628 25494 96858 106 37 0.35
HNSC Head-Neck Squamous CC. 11 57964 793 17248 21520 97539 443 152 0.34
KIRC Kidney Renal Clear CC. 9 57964 725 10392 22972 92065 249 62 0.25
KIRP Cervical Kidney RP. CC. 6 57964 593 8312 32525 99403 167 20 0.12
LAML Acute Myeloid Leukemia 7 57962 882 2176 29132 90162 35 14 0.40
LGG Low Grade Glioma 10 57964 645 9235 22297 90154 419 77 0.18
LIHC Liver Hepatocellular C. 11 57964 776 11821 20994 91569 159 35 0.22
LUAD Lung Adenocarcinoma 9 57964 799 18388 23681 100844 426 101 0.24
LUSC Lung Squamous CC. 9 57964 895 18500 23524 100895 418 132 0.32
OV Ovarian Cancer 6 57447 975 13298 24508 96237 219 109 0.50
PAAD Pancreatic AC. 10 57964 612 12392 22348 93329 124 52 0.42
SARC Sarcoma 11 57964 778 10001 22842 91599 126 38 0.30
SKCM Skin Cutaneous M. 9 57964 1002 18593 22248 99819 249 87 0.35
STAD Stomach AC. 7 57964 787 18581 26027 103369 295 62 0.21
UCEC Uterine Corpus EC. 11 57447 866 21053 23978 103358 405 38 0.09
4 Results
4.1 Failures and refinement of the study design
For some CV iterations the model fitting was not successful, leading to NAs for the assessment mea-
sures for these iterations. This is common in benchmark experiments of larger scale (Bischl et al.,
2013). To cope with such modeling failures we follow strategies described previously (Bischl et al.,
2013; Probst et al., 2019). If a learner fails in more than 20 % of the CV iterations for a given
dataset, we assign (for the failing iterations) values of the performance measures corresponding to
random prediction (0.25 for ibrier and 0.5 for cindex) and the mean of the other iterations for the
computation time and the number of selected features. If a learner fails in less than 20 %, the
performance means of the successful iterations are assigned for all measures.
Besides such modeling failures, for two methods more general issues related to usability occurred
while conducting the experiment. First of all, not all methods could be run on the same system.
For the majority of the methods we used the Linux distribution Ubuntu 14.04, but using rfsrc
together with batchtools under Ubuntu was not possible, so it was run using Windows 7. If no
parallelization is applied via batchtools, rfsrc also works using Ubuntu.
In contrast, SGL did not work using Windows 7, but worked using Ubuntu irrespective of the
parallelization issue. Using SGL with the considered large numbers of features always leads to a
fatal error in R under Windows. The extremely long computation times for SGL were problematic.
Since we received no feedback from the authors, we used the standard settings. These lead to
computations lasting several days for one single model fit for large datasets. Altering some of the
parameters did not strongly reduce the computational burden. Running the whole experiment as
planned was thus not possible for SGL. Here we briefly present the results of SGL which could be
obtained based on four of the smallest datasets. For the rest of the study we exclude SGL from
the analysis. On average over all iterations and the four datasets, SGL leads to a cindex of 0.58
and an ibrier of 0.24. The resulting models are neither sparse on feature level, with an average
of 4083 selected features, nor on group level. The mean computation time of 5.7 hours for one
CV-iteration confirms the problem of extremely long computation times. In comparison, the next
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slowest method needs 1.2 hours for one iteration, on average over all datasets. Table 3 shows the
performance values of SGL for each of the four datasets and the mean values.
Table 3: Performance of SGL on four small datasets. Column “all” represents the total number of selected features, the
subsequent columns the numbers of selected features of the respective groups.
data cindex ibrier time all clin cnv mirna rna mut
LAML 0.496 0.231 1.9 8149 0.5 7822 4.7 0 323
LIHC 0.533 0.198 9.0 3617 0.3 3250 28 264 75
PAAD 0.650 0.255 4.5 1483 3.2 62 30 12 1375
SARC 0.629 0.278 7.5 3081 2.7 1906 51 40 1082
mean 0.58 0.24 5.7 4083 1.7 3260 28 79 714
4.2 Computation time
Table 4 shows the average performance measures for every method and is ordered by the cin-
dex. All values are obtained by—firstly—averaging over the outer-resampling CV-iterations and—
secondly—averaging over the datasets. For the methods not yielding model coefficients the corre-
sponding cells contains “-”.
The eighth column of Table 4 displays the mean computation time. The computation times
are measured as the time needed for model fitting (training time). The fastest procedures are
standard Lasso and ranger, followed by glmboost and the CoxBoost variants. The three penalized
regression methods using group structure (IPF-Lasso, priority-Lasso, GRridge) are about 2 to 3
times slower, with GRridge being the fastest of the three methods. rfsrc needs about as much time
as prioritylasso and ipflasso. Of the two prioritylasso variants the one favoring clinical features is
a little slower. Finally, blockForest is the slowest method.
Of course, the computation times depend on the size of the datasets. Figure 1 displays the
mean computation time of one outer-resampling iteration for the different learners and datasets.
The datasets are ordered from smallest (LAML) to largest (BRCA). It can also be seen that the
effective number of cases influences the computation time. COAD and KIRP are among the smaller
datasets with 17 (9 %) and 20 (12 %) events, respectively. IPF-Lasso and priority-Lasso yield a
substantial increase in computation time for these datasets.
4.3 Model sparsity
To assess sparsity, the number of non-zero coefficients of the resulting model of each CV iteration
is considered. As random forest models do not yield such coefficients, this aspect is not assessed
for random forest variants.
4.3.1 Sparsity on the level of variables
Sparsity in terms of the number of included variables is particularly interesting for practical pur-
poses, since sparse models are easier to interpret and to communicate. On average, as Table 4
shows, ipflasso leads to the sparsest models with an average of 7 variables, followed by CoxBoost
with on average 10 variables. CoxBoost favoring and Lasso are also reasonably sparse (13, 16), but
the variability is higher for Lasso (see Figure 3). glmboost, prioritylasso and prioritylasso favoring
yield models with more than 20 features (22, 26, 30). Least sparse is grridge; the average grridge
model size (984) is close to the maximum number of features to be selected (maxsel = 1000 ).
grridge seems not to be able to appropriately select variables in this setting (recall that it is not
intended to do so).
4.3.2 Sparsity on group level
Figure 2 displays the number of selected variables by group for all learners except grridge (since
grridge leads to models on a much larger scale), the random forest variants and the reference
learners. Table 4 shows that grridge chooses variables from all groups and is thus not sparse on
group level.
9
05000
10000
15000
LA
ML
ES
CA
PA
AD
SA
RC
LIH
C
CO
AD
KIR
P
OV KIR
C
SK
CM
ST
AD
BL
CA
UC
EC
LG
G
HN
SC
LU
SC
LU
AD
BR
CA
Ti
m
e 
in
 s
ec
on
ds
learner
Lasso
glmboost
CoxBoost
prioritylasso
prioritylasso favoring
CoxBoost favoring
grridge
blockForest
rfsrc
ranger
ipflasso
A
102
103
104
LA
ML
ES
CA
PA
AD
SA
RC
LIH
C
CO
AD
KIR
P
OV KIR
C
SK
CM
ST
AD
BL
CA
UC
EC
LG
G
HN
SC
LU
SC
LU
AD
BR
CA
Ti
m
e 
in
 s
ec
on
ds
 (lo
g s
ca
le)
B
Figure 1: Computation time. (A) Computation times in seconds. (B) Computation times in log(seconds). The datasets
are ordered form smallest (LAML) to largest (BRCA).
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Figure 2: Sparsity on group level. Only learners yielding model coefficients are considered. Each panel shows the number
of selected features for every feature group for the considered learners. grridge is excluded since it yields models on a
much larger scale.
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Among the other methods, IPF-Lasso yields strong sparsity on group level. Mostly clinical
features are selected. The priority-Lasso is not able to eliminate groups. Furthermore, with boosting
variants CoxBoost and glmboost and with standard Lasso no clinical features are selected. CoxBoost
favoring does not select mirna features. IPF-Lasso does not include cnv and rna features. This
exemplifies the problem of methods treating high- and low-dimensional groups equally. As already
pointed out, due to their low dimension, clinical variables get lost within the huge number of
molecular variables. It becomes obvious that this also applies for some of the molecular variables.
The mirna group is, in comparison to the other molecular groups, lower dimensional with 585 to
1002 features. Learners which do not consider group structure fail to include clinical variables and
include at most one mirna variable. CoxBoost favoring, which differentiates clinical and molecular
variables, does not select mirna features. In contrast, learners taking into account the multi-omics
group structure generally include variables of both lower dimensional groups. Using the group
structure thus prevents low-dimensional groups from being discounted.
4.4 Prediction performance
4.4.1 Overview and main findings
Figure 3 shows the distributions of the values of the performance metrics across the datasets. Again,
grridge is excluded from the sparsity panel. Three important findings can be highlighted. First
of all, regarding Figure 3, most of the learners perform better than the Kaplan-Meier estimate
(indicated by the dashed horizontal line). This indicates that using the variables is, in general,
useful. Only Lasso performs worse than the Kaplan-Meier-estimate (based on the ibrier). Secondly,
only blockForest outperforms the reference clinical Cox model (red horizontal line), which stresses
the importance of the clinical variables for these datasets. Finally, methods taking into account
the group structure in some way in general outperform the naive methods according to the cindex.
4.4.2 Comparing prediction methods
All analyses in this section refer to Table 4.
Naive methods: The learners CoxBoost, glmboost, rfsrc, ranger and standard Lasso are fit
with the naive strategy. In general, the results are not consistent over the two measures. According
to the cindex, random forest performs best, regardless of which implementation is used, followed
by likelihood-based boosting and Lasso. Model-based boosting performs worst. All methods are
at least slightly better than the Kaplan-Meier estimate. With regards to the ibrier, however,
likelihood-based boosting performs best. Moreover, model-based boosting performs better than
Lasso, but still gets outperformed by the random forest variants which are close to likelihood-based
boosting. To sum up, although the results differ depending on the considered measure, random
forest shows a tendency to outperform the other methods, since it performs best based on the
cindex and is among the best methods based on the ibrier.
Methods not favoring clinical features: The learners block forest, ipflasso, prioritylasso,
and grridge use the group structure but do not favor clinical features. The random forest variant
blockForest outperforms the other methods. It performs better on average than any other method
based on both measures. Among the penalized regression methods, priority-Lasso performs best
according to the cindex and IPF-Lasso according to the ibrier. GRridge ranks second according to
the cindex and third according to the ibrier. Moreover, priority-Lasso and GRridge perform equal
to or even worse than the Kaplan-Meier estimate based on the ibrier. Since IPF-Lasso yields the
sparsest models, it might be preferable when sparsity is important.
Methods favoring clinical features: There are two learners favoring clinical features: Cox-
Boost favoring and prioritylasso favoring. The results are unambiguous with CoxBoost favoring
performing better than prioritylasso favoring. Furthermore, both learners perform better than the
Kaplan-Meier estimate based on the cindex, but only CoxBoost favoring performs better than the
Kaplan-Meier estimate based on the ibrier. Thus, according to these findings, likelihood-based
boosting yields better results than priority-Lasso when clinical variables are favored, even though
priority-Lasso here further distinguishes the molecular data.
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Table 4: Average learner performances. The values are obtained by averaging over the CV-Iterations and datasets. The
time is measured in minutes. For learners not yielding model coefficients, the corresponding measures are set to “-”.
Column “all” represents the total number of selected features, the subsequent columns the numbers of selected features
of the respective groups. The “ci” columns display the 95 % confidence intervals for the means based on quantiles of the
t-distribution. The total number of features may differ from the sum of features in each group due to rounding errors.
cindex ibrier
learner mean sd ci mean sd ci time all clin cnv mirna rna mut
blockForest 0.620 0.072 [0.584, 0.656] 0.174 0.042 [0.153, 0.195] 80 - - - - - -
Clinical only 0.618 0.060 [0.588, 0.648] 0.175 0.038 [0.156, 0.194] 0 8 8 - - - -
CoxBoost favoring 0.618 0.057 [0.589, 0.646] 0.174 0.036 [0.156, 0.192] 13 13 8 1 0 3 1
prioritylasso favoring 0.607 0.056 [0.579, 0.635] 0.181 0.040 [0.161, 0.201] 39 30 8 4 6 6 5
prioritylasso 0.591 0.068 [0.558, 0.625] 0.180 0.037 [0.162, 0.199] 32 26 4 4 7 7 4
grridge 0.587 0.069 [0.553, 0.622] 0.181 0.044 [0.159, 0.203] 28 984 2 332 19 540 91
ipflasso 0.578 0.100 [0.528, 0.628] 0.176 0.034 [0.159, 0.193] 33 7 5 0 1 0 1
rfsrc 0.567 0.078 [0.528, 0.606] 0.182 0.045 [0.160, 0.204] 36 - - - - - -
ranger 0.562 0.068 [0.529, 0.596] 0.179 0.045 [0.157, 0.202] 10 - - - - - -
CoxBoost 0.552 0.080 [0.512, 0.592] 0.175 0.039 [0.155, 0.194] 14 10 0 1 1 5 2
Lasso 0.546 0.089 [0.502, 0.591] 0.198 0.034 [0.181, 0.215] 8 16 0 2 1 8 5
glmboost 0.542 0.104 [0.490, 0.593] 0.188 0.037 [0.169, 0.206] 12 22 0 3 1 10 7
Kaplan-Meier 0.500 0.000 [0.5, 0.5] 0.180 0.040 [0.160, 0.200] 0 - - - - - -
Figure 3: Performance of the learners - A: cindex. B: ibrier. C: Total number of selected features; only learners yielding
model coefficients are included and grridge is excluded since it yields models on a much larger scale. The solid red and
dashed black horizontal lines correspond to the median performance of the clinical-only-model and the Kaplan-Meier-
estimate, respectively. Colours indicate membership to one of the general modeling approaches: penalised regression
(blue), boosting (orange), random forest (green), reference methods (black). Abbreviations: KM = Kaplan-Meier, Lasso
= Lasso, glmB = glmboost, CoxB = CoxBoost, CoxPH = Clinical only, prior = prioritylasso, prior_f = prioritylasso
favoring, IPF = ipflasso, CoxB_f = CoxB favoring, GRr = grridge, BF = blockForest, rfsrc = rfsrc, ranger = ranger.
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However, when comparing the described performances, one has to take into account the small
differences in performance and the variability of the method performances across datasets. As
the confidence intervals in Table 4 show, conclusions about the superiority of one method over
another should be treated with caution. Moreover, paired two-sided t-tests comparing, for example,
blockForest with CoxBoost favoring and the Clinical only model show no statistically significant
differences in performance with p-values of 0.81 and 0.86 (cindex) and 0.95 and 0.78 (ibrier). For
all t-tests in the study, the normal distribution assumption was checked with Shapiro-Wilk-tests
and Q-Q-plots.
4.4.3 Using multi-omics data
Added predictive value: To assess the added predictive value of the molecular data, we
follow approach A proposed by Boulesteix and Sauerbrei (2011), thus comparing learners obtained
by only using clinical features and combined learners, i.e. learners using clinical and molecular
variables. Since it is emphasized that for this validation approach the combined learners should
not be derived by the naive strategy, these learners are not considered here.
In general, the findings indicate that the multi-omics data may have the potential to add
predictive value. First of all, blockForest outperforms the Cox model based on both measures.
Secondly, as Table 5 shows, there are several datasets for which there is at least one learner that takes
the group structure into account and outperforms the clinical learner. For some of the datasets, e.g.
LAML and COAD, the performance differences are substantial. Thus, using additional molecular
data leads to better prediction performances in some of the considered cases. On the other hand,
it must take into account that in the other cases the differences are small and, again regarding the
confidence intervals, one has to be careful when drawing conclusions about the superiority over the
Cox model. Moreover, for six datasets the Cox model does not get outperformed at all by methods
which use the omics data. This raises serious concerns regarding a beneficial effect of the omics
data in general.
Including group structure: In general, the results suggest that using the naive strategy of
treating clinical and molecular variables equally leads to a worse performance in comparison to
methods that take the group structure into account. Table 6 shows the mean performance of the
naive learners and the structured learners (both favoring and not favoring the clinical features) by
dataset. Each value is computed as average over the naive respectively the structured learner’s
mean cindex and ibrier values.
Only in five cases is the average performance of the naive learners better than the average
performance of the structured learners: Regarding the ibrier, the naive learners perform better
than the structured learners for four datasets; regarding the cindex, only for the LGG dataset
is the performance of the naive learners higher than the performance of the structured learners.
Unpaired, one-sided t-tests for the five naive and the six structured learners, using the mean
performance values of the individual methods over the datasets as observations, yield p-values of
0.0002 and 0.0904 for the cindex and ibrier.
Favoring clinical features: According to our findings, favoring clinical variables leads to
better prediction results. For likelihood-based boosting, this is in line with the findings of others (see
De Bin (2016) and the reference therein). Differentiating the clinical variables from the molecular
features strongly increases the prediction performance of likelihood-based boosting (CoxBoost and
CoxBoost favoring), according to the average cindex. Favoring clinical features raises likelihood-
based boosting from one of the worst to one of the best performing methods. Moreover, our findings
show this might also hold for methods which use the multi-omics group structure. For priority-
Lasso the increase is not as strong, but still notable when considering the cindex. Yet, the ibrier
does not confirm this.
5 Discussion
In general, one should be very careful when interpreting the results of our benchmark experiment
and drawing conclusions. Most importantly, the findings highly depend on the considered prediction
performance measure, as the method ranking changes drastically between the two measures. For
example, CoxBoost performs poorly based on the cindex but performs third best regarding the
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Table 5: Assessment of the added predictive value of the molecular variables by dataset. The second and seventh
column show the best performing learners for the respective dataset and measure, the “cindex” and “ibrier” column the
performances of these learners. In the cases where the clinical only model is outperformed, the “ref.” columns show
the corresponding cindex and ibrier values of the reference Cox model only using clinical variables. The “ci” columns
show the 95 % confidence intervals for the respective performance values based on quantiles of the t-distribution. Bold
numbers indicate datasets for which there is at least one method using the group structure and outperforming the Cox
model regarding both measures.
data learner cindex ci ref. ci learner ibrier ci ref. ci
BLCA CoxBoost favoring 0.640 [0.612, 0.668] 0.633 [0.607, 0.659] CoxBoost favoring 0.19 [0.181, 0.199] 0.192 [0.183, 0.201]
BRCA CoxBoost favoring 0.643 [0.618, 0.669] 0.637 [0.608, 0.666] blockForest 0.141 [0.134, 0.149] 0.147 [0.137, 0.158]
COAD blockForest 0.656 [0.586, 0.725] 0.541 [0.475, 0.608] blockForest 0.087 [0.075, 0.099] 0.101 [0.088, 0.115]
ESCA Clinical only 0.574 [0.536, 0.612] - - ipflasso 0.209 [0.198, 0.221] 0.214 [0.199, 0.228]
HNSC blockForest 0.582 [0.554, 0.610] 0.554 [0.519, 0.588] glmboost 0.202 [0.193, 0.211] 0.210 [0.201, 0.220]
KIRC Clinical only 0.761 [0.734, 0.789] - - ipflasso 0.144 [0.138, 0.149] 0.146 [0.140, 0.152]
KIRP rfsrc 0.648 [0.582, 0.713] 0.572 [0.502, 0.641] ranger 0.118 [0.106, 0.131] 0.140 [0.117, 0.163]
LAML ranger 0.709 [0.651, 0.766] 0.596 [0.534, 0.657] ranger 0.182 [0.165, 0.199] 0.231 [0.200, 0.263]
LGG glmboost 0.749 [0.719, 0.779] 0.652 [0.618, 0.685] Lasso 0.145 [0.132, 0.157] 0.168 [0.154, 0.181]
LIHC grridge 0.602 [0.560, 0.645] 0.586 [0.542, 0.630] ranger 0.146 [0.135, 0.157] 0.169 [0.158, 0.180]
LUAD prioritylasso 0.665 [0.640, 0.690] 0.663 [0.631, 0.695] CoxBoost favoring 0.172 [0.160, 0.183] 0.172 [0.161, 0.183]
LUSC prioritylasso favoring 0.537 [0.502, 0.572] 0.531 [0.502, 0.561] grridge 0.210 [0.203, 0.217] 0.216 [0.205, 0.227]
OV prioritylasso 0.600 [0.582, 0.618] 0.598 [0.580, 0.617] ipflasso 0.169 [0.163, 0.174] 0.173 [0.167, 0.179]
PAAD prioritylasso favoring 0.686 [0.658, 0.714] 0.683 [0.655, 0.712] Clinical only 0.190 [0.178, 0.202] - -
SARC blockForest 0.685 [0.651, 0.720] 0.673 [0.637, 0.709] glmboost 0.179 [0.167, 0.190] 0.202 [0.188, 0.217]
SKCM blockForest 0.597 [0.556, 0.639] 0.581 [0.540, 0.623] Clinical only 0.191 [0.185, 0.198] - -
STAD Clinical only 0.598 [0.555, 0.641] - - Clinical only 0.192 [0.182, 0.202] - -
UCEC Clinical only 0.686 [0.581, 0.791] - - ipflasso 0.091 [0.079, 0.102] 0.092 [0.080, 0.105]
Table 6: Comparing naive learners and structured learners. The performance of structured learners, i.e. learners using
the group structure, and naive learners are compared for every dataset. The cindex and ibrier columns show the mean
performance values for the corresponding dataset and learner types. Bold values indicate better values for the given
dataset.
cindex ibrier
data structured naive structured naive
BLCA 0.618 0.580 0.198 0.203
BRCA 0.598 0.467 0.152 0.180
COAD 0.518 0.452 0.104 0.114
ESCA 0.506 0.405 0.235 0.233
HNSC 0.562 0.549 0.210 0.214
KIRC 0.721 0.671 0.154 0.159
KIRP 0.560 0.527 0.132 0.133
LAML 0.634 0.548 0.207 0.211
LGG 0.695 0.721 0.169 0.158
LIHC 0.566 0.530 0.171 0.164
LUAD 0.636 0.519 0.181 0.199
LUSC 0.501 0.406 0.220 0.231
OV 0.575 0.393 0.172 0.189
PAAD 0.663 0.581 0.196 0.205
SARC 0.667 0.624 0.197 0.180
SKCM 0.580 0.478 0.200 0.221
STAD 0.556 0.504 0.199 0.211
UCEC 0.646 0.526 0.103 0.115
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ibrier. These findings indicate that the performance of a method may change dramatically if
a different performance measure is used for its assessment. Moreover, according to ibrier, two
methods perform better than the Cox model (though only slightly), and six methods perform
worse than the Kaplan-Meier estimate.
Another important aspect of the performance assessment is, as shown in Figure 3 and Table
5, the variability across datasets. The superiority of one method over the other not only strongly
depends on the considered performance measure but also, most importantly, on the considered
datasets. This stresses the importance of large-scale benchmarks, like this one, which use many
datasets. Since the variability between datasets is huge, we need many datasets—a fact well-
known by statisticians performing sample size calculations, which however tends to be ignored
when designing benchmark experiments using real datasets (Boulesteix et al., 2015). If we had
conducted our study with, say, 3, 5 or 10 datasets (as usual in the literature), we would have
obtained different—more unstable—results.
Regarding prediction performance, blockForest outperforms the other methods on average over
all datasets. Moreover, it is the only method which outperforms the simple Cox model on average
regarding both measures. The other methods using the molecular data do not perform better than
the simple Cox model. The better prediction performance of blockForest, however, comes at the
price of long computation times. Apart from SGL, blockForest is the slowest method. The fastest
learners, standard Lasso and ranger, are about 10 times faster and blockForest is still 2 times
slower than the next slowest learner prioritylasso favoring. Moreover, like the other random forest
variants, it does not yield easily interpretable models, even though the strengths of the variables
can be assessed via the variable importance measure(s) output as a by-product of the random forest
algorithms. Thus, taking the other assessment dimensions into account, e.g. CoxBoost favoring
clinical features is very competitive. It is quite fast, leads to reasonably sparse models at group
and feature level and yields performances only slightly worse than (cindex) or equal to (ibrier)
blockForest.
From a practical perspective, even simpler modeling approaches, such as a simple Cox model
using clinical variables only, might be preferable. This model is easily interpretable, needs only
a fraction of the computation time and, with a mean cindex of 0.618 and a mean ibrier of 0.175,
performs only slightly worse than blockForest (0.620 and 0.172) and comparable to or even better
than all other methods. Note, however, that blockForest also offers the possibility of favoring clini-
cal covariates using the argument always.select.block of the blockfor function. Hornung and Wright
(2019), show that this can improve the prediction performance of block forest considerably. How-
ever, since this option was not yet available at the time of conduction of the analyses performed
for the current paper, we were not able to consider this block forest variant here.
In general, conclusions about the superiority of one method over the other with respect to the
prediction performance must be drawn with caution, as the differences in performance can be very
small and the confidence intervals often show a remarkable overlap. Exemplary t-tests comparing
blockForest with CoxBoost favoring and the Clinical only model showed no significant differences
in performance.
More generally, it should be noted that the choice of a method should result from the simultane-
ous consideration of various aspects beyond performance. If (i) performance is the main criterion,
(ii) the model is intended solely as a prediction tool, and implemented, say, as a shiny application
(Chang et al., 2018), and (iii) sparsity and interpretability are not considered important, blockFor-
est is certainly a very good choice. Other methods may prove attractive in different situations.
Finally, let us note that one of the methods that did not perform very well in the present study in
terms of performance, priority-Lasso, may perform better in practice when accurate prior knowl-
edge on the groups of variables is available, and allows the user to favor some of the groups—a
dimension that could not be taken into account in our comparison study.
A potential limitation of our study is that the datasets were already used by Hornung and Wright
(2019) in their comparison study. Since they selected the most promising blockForest based on this
comparison study, our results may be slightly optimistic regarding the performance of blockFor-
est—a bias mechanism that has been previously described (Jelizarow et al., 2010). More precisely,
Hornung and Wright (2019) initially considered five different variants of random forest taking the
block structure into account and identified the best-performing variant using a collection of 20
datasets including the 18 considered in our study. They named this best-performing variant “block
forest”. It is in theory possible that part of the superiority of the selected “block forest” variant
on the specific 20 datasets is due to chance. In this case, our study that uses 18 of these datasets
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again would (slightly) favor block forest. However, Hornung and Wright (2019) used two addi-
tional datasets, did not use the same sets of clinical variables, and—to reduce the computational
burden—, in the cases of groups with more than 2,500 variables, they used only a subset of 2,500
variables. To sum up, the benchmark by Hornung and Wright (2019) and ours are largely different
even if partly based on data from the same cancer studies. It is thus unlikely that our study is
noticeably biased, although such a bias is possible in principle.
Regarding the advantage of favoring the clinical variables, it is important to note that it strongly
depends on the level of predictive information contained in these variables. If clinical variables
contain less information than for the datasets used in our analysis, favoring of these covariates might
be less useful than they were found to be in this study, or even detrimental. While we strongly
recommend considering favoring the clinical variables, this should not necessarily be performed by
default.
Extending the benchmark to further methods (e.g., methods that do not rely on the proportional
hazards assumption, which are only represented by random forest in our study) and further data
pre-processing approaches as well as further datasets are desirable. In the same vein, it may be
interesting to consider alternative procedures to handle model failures in the outer-resampling
process, which may lead to different results. There is to date no widely used standardized approach
to deal with NAs in this context. This issue certainly deserves further dedicated research. This
benchmark experiment is designed such that such extensions are easy to implement. Using the
provided code, further methods can be compared to the ones included in this study.
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Supplement: Method details
Let there be a feature matrix X and G feature groups, then x
(g)
·1 , ...,x
(g)
·pg denote the features of group
g, g = 1, ..., G, with pg the number of features within group g, and xi the feature vector of observation
i. Furthermore β
(g)
j indicates the corresponding coefficient of feature x
(g)
·j .
For survival outcomes the penalized-regression and the boosting methods are based on the concept
of minimizing the negative partial log-likelihood
pl(β) = −
n∑
i=1
δi

xTi β − log

∑
l∈Ri
exp(xTl β)



 (1)
rather than minimizing the sum of squared differences, with Ri the set of indices of individuals at risk
at time ti and δi ∈ {0, 1} the censoring indicator (Tibshirani, 1997; Binder and Schumacher, 2008). If
an offset term ηi is to be included in the estimation process, (1) becomes
pl(β|η) = −
n∑
i=1
δi

ηi + xTi β − log

∑
l∈Ri
exp(xTl β)



 (2)
Penalized-regression-based methods
For standard Lasso (Tibshirani, 1996, 1997), which does not regard the group structure, the estimate
in the survival setting is given by
βˆ = argmin
β
pl(β) + λ
p∑
j=1
|βj |. (3)
Large coefficient values are penalized and sparse final models result since a substantial number of co-
efficients are set to zero, if the penalty parameter λ is large enough, which is a hyper-parameter to be
tuned.
Two-step (TS) IFP-Lasso (Schulze, 2017; Boulesteix et al., 2017) is an extension of the standard
Lasso specifically designed to incorporate multi-omics group structure and based on the estimate
βˆ = argmin
β
pl(β) +
G∑
g=1
λg‖β(g)‖1, (4)
with ‖.‖1 being the L1-Norm, λg > 0 the penalty of group g and β(g) = (β(g)1 , ..., β(g)pg )T . It uses
different penalties for the specified groups by determining a vector of inverted coefficient means for
every group which are used as penalty factors. These penalty factors are determined in the first step
by fitting a preliminary model.
Priority-Lasso (Klaus et al., 2018) successively fits regression models with the estimate
βˆ(pig) = argmin
β(pig)
pl(β(pig)|ηˆ(pig−1)) + λ(pig)
ppig∑
j=1
|β(pig)j | (5)
with pi = (pi1, ..., piG) being a permutation of (1, ..., G) that indicates the priority order and ηˆ
(pig−1)
the resulting linear predictor of group pig−1. More precisely, the single estimates βˆ
(pig) are obtained by
sequentially fitting Lasso models using the features in the order of their group’s priority. The linear
predictor ηˆ
(pig−1)
i of the previous group pig−1 is used as offset for the model fit to the next group.
Sparse Group Lasso (SGL) (Simon et al., 2013) is another extension of the Lasso capable of including
group information. The estimate is given by
βˆ = argmin
β
1
n
pl(β) + (1− α)λ
G∑
g=1
√
pg||β(g)||2 + αλ||β||1 (6)
with α steering the contributions of the group-Lasso (Yuan and Lin, 2006) and the standard Lasso
penalties. This simultaneously leads to sparsity on feature as well as on group level.
Adaptive group-regularized ridge regression (GRridge) (Wiel et al., 2015) is designed to use group spe-
cific co-data, e.g. p-values known from previous studies, but multi-omics group structure may also be
regarded as co-data. The estimate is given by
βˆ = argmin
β
pl(β) +
G∑
g=1
λg
pg∑
j=1
β2j (7)
with λg = λ
′
gλ and λ a global penalty, specified by cross-validation, and λ
′
g factors which are estimated
via empirical Bayes estimation. Feature selection is achieved post-hoc by exploiting the heavy-tailed
distribution of the estimated coefficients, which clearly separates coefficients close to zero from those
further away (Wiel et al., 2015).
Boosting-based methods
Boosting is a general technique introduced in the context of classification in the machine learning
community, which has then been transferred to statistical contexts as a gradient descent in function
space (Friedman, 2001). Statistical boosting can thus be seen as a form of iterative function estimation
by fitting a series of weak models, so called base learners. In general, one is interested in a function
f that minimizes the expected loss when used to model the data. Given a target variable Y and a
matrix of independent variables X , this can be expressed as
f∗(.) = argmin
f(.)
E[ρ(Y, f(X ))], (8)
with ρ being a loss function (Bühlmann and Hothorn, 2007). The target function f∗(.) is updated
iteratively, with the number of boosting steps mstop, i.e. iterations, being the main tuning parameter.
This results in a model
fˆ∗(X) =
mstop∑
m=0
fˆ [m](X) = fˆ [0](X) + ν
mstop∑
m=1
Gˆ[m](u[m],X), (9)
with u[m] = − δ
δf
ρ(y, f)|
f=fˆ [m−1](X) being the negative gradient, G the base learner and ν the learning
rate (Hastie et al., 2009).
Model-based boosting uses simple linear models as base learners and updates only the loss minimizing
base learner per iteration, leading to an estimate where each component depends only on one feature,
i.e.
fˆ∗(X) =
mstop∑
m=0
fˆ [m](X) = fˆ [0](X) + ν
mstop∑
m=1
βˆ
[m]
j x.j, (10)
2
with βˆ
[m]
j = (x
T
·jx·j)
−1xT·juˆ
[m]. In the survival setting the negative gradient for observation i becomes
uˆ
[m]
i = δi −
∑
l∈Ri
δl
exp(xTl βˆ
[m−1])∑
k∈Rl
exp(xTk βˆ
[m−1])
. (11)
Likelihood-based boosting (Tutz and Binder, 2006), in contrast, uses a penalized version of the partial
log-likelihood as loss and the shrinkage is directly applied in the coefficient estimation step via a penalty
parameter, leading to
plLB(β
[m]) = pl(β[m]|ηˆ[m−1])− 0.5λβTPβ, (12)
where P is a p× p matrix (De Bin, 2016). As it is still an iterative procedure, the updates of previous
iterations have to be included as an offset ηˆ[m−1] = xT βˆ[m−1] in expression (12), to make use of the
information gained.
Random-forest-based methods
The following algorithm is based on Hastie et al. (2009, p. 588). To compute a random forest
1. For b = 1 to B:
1.1 Draw a bootstrap sample of size n from the training data
1.2 Fit a single tree Tb to the bootstrap sample by recursively repeat-
ing the following steps for each node, until the predefined
minimum nodesize
a) Draw mtry numbers of features randomly
b) Choose the best feature and split-point combination
c) Split the node into two daughter nodes
2. Output the tree ensemble
The extension to survival time data by Ishwaran et al. (2008) is also called random survival forest.
The split criterion is based on maximizing the difference in survival. The terminal nodesize is defined
by the minimum number of deaths d0 > 0 that should be included in the final nodes T of the trees
constituting the forest. Let t
(T )
1 < t
(T )
2 < ... < t
(T )
NT
be the NT event times in a final node T , for each
T the cumulative hazard function Λ(T )(t∗) = ∫ t∗0 λ(u)du, λ(u) the hazard rate at time point u, is
computed via the Nelson-Aalen estimator
Λˆ(T )(t∗) =
∑
t
(T )
l
≤t∗
d
(T )
l
n
(T )
l
, (13)
with d
(T )
l the number of deaths and n
(T )
l = |R
(T )
l | the number of individuals at risk at time t
(T )
l .
For prediction, the estimates are averaged across the trees to obtain the ensemble cumulative hazard
function.
Block forest (Hornung and Wright, 2019) modifies the split point selection of random (survival)
forest to incorporate the block structure of multi-omics data. The block choice is randomized and the
split criterion values are weighted blockwise in the split-point selection procedure.
3
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